TACSTD2 and pancreatic neoplasm: For pancreatic cancer, although monoclonal antibodies targeting integrin α3, Mucins, EGFR, TROP2 and α6β4 have demonstrated efficacy in pancreatic tumor xenograft models, their clinical translation has been limited with minimal survival benefits observed in patients [17–19].